We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0VGI market cap is 0. The company's latest EPS is USD 0.0821 and P/E is 391.72.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 152k | 152k | 6.69M | 2.79M | 233.66M |
| Operating Income | -169.06M | -273.59M | -344.77M | -192.84M | 20.63M |
| Net Income | -172.87M | -279.38M | -348.1M | -198.34M | 12.67M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 163.01M | 625.64M | 379.63M | 193.57M | 329.59M |
| Total Liabilities | 124.4M | 106.29M | 142.48M | 134.99M | 169.09M |
| Total Equity | 38.62M | 519.35M | 237.15M | 58.59M | 160.5M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -132.81M | -214.51M | -295.63M | -176.17M | -31.41M |
| Investing | -718k | -24.51M | -332k | -20.01M | -50.65M |
| Financing | 204.21M | 679.83M | 41.42M | -391k | 72.71M |
| Market Cap | 0 |
| Price to Earnings Ratio | 391.72 |
| Price to Sales Ratio | 21.25 |
| Price to Cash Ratio | 53.44 |
| Price to Book Ratio | 30.94 |
| Dividend Yield | - |
| Shares Outstanding | 154.42M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Tg Therapeutics Inc |
| Address |
corporation trust center 1209 orange st wilmington, delaware 19801 |
| Website | https://www.tgtherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
